Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-5223
- Development stage
- Phase 1
- Lead developer
- Dong-A ST
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DA-5223 is an investigational pharmaceutical drug developed by Dong-A ST. It is currently undergoing clinical evaluation in Phase 1 trials to assess its safety, tolerability, and pharmacokinetics in healthy adult subjects. There is also a closely related formulation, DA-5223-R, being studied in comparison. DA-5223 is being tested for its pharmacokinetic properties under different conditions, including with and without food. The precise mechanism of action, molecular structure, and therapeutic indications have not been disclosed in publicly available sources. The drug is not approved for any clinical use as of July 2025[1][2][3][4][5][6][7][9].
Beyond the preview
Go deeper on DA-5223.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-5223.